🔗 Share this article

The first new treatments for gonorrhoea in many years are being viewed as a "significant breakthrough" in the battle against superbug strains of the infection, according to researchers.

A Worldwide Challenge

Gonorrhoea infections are increasing globally, with estimates suggesting more than 82 million instances each year. Especially elevated rates are seen in Africa and countries within the WHO's Western Pacific region, which spans from China and Mongolia to New Zealand. Across England, cases have hit a record high, while figures across Europe in 2023 were triple the level compared to figures for 2014.

“The authorization of new treatments for gonorrhoea is an critical and opportune step in the reality of rising global incidence, increasing antimicrobial resistance and the highly restricted available drugs at this time.”

Health officials are particularly alarmed about the rise in drug-resistant strains. The global health body has listed it as a "priority pathogen". A tracking program revealed that the effectiveness of key first-line drugs like cefixime and ceftriaxone increased dramatically between 2022 and 2024.

A Pair of Novel Treatment Options Secure Approval

Zoliflodacin, also known as a brand name, was cleared by the American regulatory agency in mid-December for treating gonorrhoea. This STI can lead to significant complications, including infertility. Experts believe that specific application of this new drug will help slow the emergence of superbugs.

Another new antibiotic, created by the drugmaker GlaxoSmithKline, also received approval in concurrent days. This drug, which is additionally indicated for urinary tract infections, was shown in trials to be successful in treating drug-resistant strains of the gonorrhoea bacteria.

An Innovative Development Model

Zoliflodacin stemmed from a unique collaborative effort for drug creation. The charitable organization GARDP collaborated with the drug firm Innoviva to bring it to fruition.

“This authorization signifies a huge turning point in the management of superbug gonorrhoea, which up to this point has been staying ahead of our drug pipeline.”

Research Study Outcomes and Global Access

Based on findings released by a major medical journal, zoliflodacin eradicated more than 90% of genital gonorrhoea infections. This puts it on an equal footing with the typical regimen, which uses a dual-drug approach. The study enrolled nearly 1,000 volunteers from various regions including the United States, Thailand, South Africa, and European nations.

Through the arrangement of its collaboration, GARDP has the rights to register and commercialise the drug in a wide range of developing nations.

Clinicians treating patients have expressed hope. Access to a single-dose, oral treatment like this is seen as a "critical tool" for gonorrhoea control. This is considered crucial to lessen the impact of the illness for patients and to prevent the spread of untreatable gonorrhoea globally.